CN113521171A - Essential oil for relieving rheumatoid arthritis - Google Patents

Essential oil for relieving rheumatoid arthritis Download PDF

Info

Publication number
CN113521171A
CN113521171A CN202110915803.XA CN202110915803A CN113521171A CN 113521171 A CN113521171 A CN 113521171A CN 202110915803 A CN202110915803 A CN 202110915803A CN 113521171 A CN113521171 A CN 113521171A
Authority
CN
China
Prior art keywords
essential oil
rheumatoid arthritis
effect
relieving
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110915803.XA
Other languages
Chinese (zh)
Inventor
洪辉云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Xiangyuan Biotechnology Development Co ltd
Original Assignee
Fujian Xiangyuan Biotechnology Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Xiangyuan Biotechnology Development Co ltd filed Critical Fujian Xiangyuan Biotechnology Development Co ltd
Priority to CN202110915803.XA priority Critical patent/CN113521171A/en
Publication of CN113521171A publication Critical patent/CN113521171A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B9/00—Essential oils; Perfumes

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of essential oil, in particular to essential oil for relieving rheumatoid arthritis, which comprises a plurality of natural plant components such as Zhejiang wintersweet essential oil, grassleaf sweelflag rhizome essential oil, frankincense essential oil, litsea cubeba essential oil, fir essential oil and the like, wherein a TNF-alpha method, a CCK-8 method and ELISA are utilized to act on MH7A cells to construct a synoviocyte inflammation model of joint fibroblast, the effect of the essential oil on the synovium of the joint is simulated, the influence of the essential oil with different concentrations on human mast cell LAD2 is measured by the CCK-8 method and C48/80 method to simulate the influence of the essential oil on an immune system, the essential oil has positive effects on the inflammation of the joint synovium and the disorder of immune cell functions, has practical significance and popularization value, and can be used for relieving the development of products for the rheumatoid arthritis.

Description

Essential oil for relieving rheumatoid arthritis
Technical Field
The invention relates to the technical field of essential oil, in particular to essential oil for relieving rheumatoid arthritis.
Background
Rheumatoid Arthritis (RA) is a chronic, inflammatory and systemic autoimmune disease, which is caused by symmetrical attack of small joints such as hands and wrists, joint redness and pain at the initial stage, decreased joint function and mobility, morning stiffness and other symptoms, and is characterized by a large amount of inflammatory cell infiltration and abnormal synovial tissue proliferation as main pathological features, and serious symptoms can cause damage and erosion of articular cartilage, joint deformity and function loss, even disability, and serious damage to physical and mental health of patients. RA is widely existed in various regions and families in the world, the incidence rate of adult RA in the world is up to 1 percent, the incidence rate of adult RA in China is up to 0.34 percent, and the medicine has the clinical characteristics of high disability rate and low cure rate. At present, the pathogenic mechanism of rheumatoid arthritis is not completely elucidated, the disease is considered to be autoimmune disease at present, genetic, environmental, infection and immune factors can play a role together, and clinical treatment mainly aims at relieving symptoms and improving life quality. At present, the drugs clinically used for treating RA mainly include antirheumatic drugs, nonsteroidal anti-inflammatory drugs, steroid hormone drugs, biological agents and the like for improving the disease condition. However, the clinical use of these drugs is limited by side effects associated with long-term use, such as gastrointestinal reactions, hepatic and renal dysfunction, and other systemic toxicities caused by free drug entry into the systemic circulation. The natural medicine has the characteristics of low cost, weak drug resistance and less side effects, so that the search for economic and effective natural medicine for resisting rheumatoid arthritis becomes an important challenge for domestic and foreign medical research.
The method extracts and analyzes the main components of several aromatic plant essential oils, optimizes the extraction process, and infers the potential drug effect of the essential oils by analyzing the components; RA has complex pathogenesis, immune cell dysfunction and synovial cell hyperproliferation are two main pathogenic factors, and the pathological characteristics of inflammation, synovial hyperplasia and the like of an organism are caused. The corresponding immune cells and synoviocytes are the key cells involved in the pathogenesis of RA. The invention provides essential oil extracted from natural plants, and researches the effect of the essential oil on joint synovium in rheumatoid arthritis and the influence on an immune system, and the effect and the potential development value on the rheumatoid arthritis.
Disclosure of Invention
The invention aims to provide an essential oil for relieving rheumatoid arthritis so as to solve the problems mentioned in the background technology.
In order to achieve the above purpose, the invention provides essential oil for relieving rheumatoid arthritis, which comprises Zhejiang wintersweet essential oil, grassleaf sweelflag rhizome essential oil, frankincense essential oil, litsea cubeba essential oil and fir essential oil.
Preferably, 1-10g of Zhejiang wintersweet essential oil, 1-10g of rhizoma acori graminei essential oil, 1-5g of frankincense essential oil, 1-10g of litsea cubeba essential oil and 1-5g of fir essential oil.
Preferably, the essential oil of hyssop is also included.
Preferably, the hyssop essential oil is 1-10 g.
Preferably, rosemary essential oil is also included.
Preferably, the rosemary essential oil is 1-5 g.
Preferably, the rosemary essential oil is of verbenone type.
Preferably, a diluent is also included.
Preferably, the diluent accounts for 50-100% of the total mass of the rest components.
Preferably, the diluent is black grass oil in specific implementation.
The essential oil was analyzed for its main components, hyssop essential oil, acorus gramineus essential oil (three parts of root, leaf, whole plant) and zhejiang wintersweet essential oil, by GC-MS, to obtain tables 1, 2 and 3.
TABLE 1 essential ingredients of essential oil of hyssop
Serial number Name of English CAS Name of Chinese Relative percentage content (%)
1 alpha-Pinene 80-56-8 Alpha-pinene 0.4779
2 3-Thujene 2867-05-2 3-arborvitae 0.2503
3 Camphene 79-92-5 Camphene 0.1063
4 beta-Pinene 127-91-3 Beta-pinene 8.0038
5 Sabinene 3387-41-5 Sabinene derivatives 1.6185
6 Myrcene 123-35-3 Myrcene 1.4077
7 Limonene 138-86-3 Limonene 0.9502
8 beta-Phellandrene 555-10-2 Beta-phellandrene 1.5093
9 trans-beta-Ocimene 3779-61-1 Trans-beta-ocimene 0.2903
10 gamma-Terpinene 99-85-4 Gamma-terpinene, terpinene 0.1126
11 Ocimene 13877-91-3 Ocimum basilicum 1.2941
12 Terpinolene 586-62-9 Terpinolene 0.0911
13 Myrtenyl methyl ether 202527-57-9 Myrtle methyl ether 1.5591
14 Thujone 546-80-5 Arborvitae ketone 0.4358
15 Elemene isomer 1000414-93-6 Elemene isomers 0.356
16 trans-3-Pinanone 547-60-4 Trans-3-pinone 30.0013
17 (-)-.beta.-Bourbonene 5208-59-3 Beta-bourbonene 0.6975
18 cis-3-Pinanone 15358-88-0 Cis-3-pinone 22.0211
19 Linalool 78-70-6 Linalool 0.8077
20 Pinocarvone 30460-92-5 Rosin apinone 1.2191
21 beta-Caryophyllene 87-44-5 Trans-caryophyllene 1.7874
22 Terpinen-4-ol 562-74-3 4-terpineol 0.1877
23 (-)-Myrtenal 564-94-3 (-) -myrtle enal (myrtle aldehyde) 0.146
24 Alloaromadendrene 25246-27-9 Myrcene 0.8553
25 (-)-trans-Pinocarveol 547-61-5 (-) -trans-rosinol 0.0772
26 Estragole 140-67-0 Aicaogan 0.2076
27 Humulene 6753-98-6 Alpha-humulene 0.4615
28 (E)-beta-Famesene 18794-84-8 Trans-beta-farnesene 0.1766
29 Methyl myrtenate 30649-97-9 Myrtle acid methyl ester 0.2545
30 alpha-Terpineol 98-55-5 Alpha-terpineol 0.5965
31 Germacrene D 23986-74-5 Dextro-germacrene 3.2805
32 Bicyclogermacrene 24703-35-3 Bicyclic germacrene 4.371
33 (+)-delta-Cadinene 483-76-1 (+) -delta-cubebene 0.203
34 (-)-Myrtenol 515-00-4 Myrtenol 3.6712
35 Caryophyllene oxide 1139-30-6 Dianthus caryophyllus extract 0.1753
36 Methyleugenol 93-15-2 Methyl eugenol 0.3315
37 Ledol 577-27-5 Horn alcohol 0.1633
38 (-)-Globulol 489-41-8 Eucalyptol 0.1487
39 Himbaccol 552-02-3 Melaleuca alternifolia alcohol 0.0826
40 Elemol 639-99-6 Elemenol 6.5247
41 Spathulenol 6750-60-3 Baba alcohol 0.1867
42 gamma-Eudesmol 1209-71-8 Gamma-eucalyptol 0.9209
43 alpha-Eudesmol 473-16-5 Alpha-eucalyptol 0.4007
44 beta-Eudesmol 473-15-4 Beta-eucalyptol 0.4848
45 alpha-Cadinol 481-34-5 Alpha-cubebinol 0.1076
46 Phytol 150-86-7 Plant alcohol 0.2573
According to the GC-MS analysis results, trans-3-pinone (30.0013%) and cis-3-pinone (22.0211%) were the main components of the essential oil of hyssop.
TABLE 2 essential oil of Acorus tatarinowii Schott
Serial number Name of English CAS Name of Chinese All-purpose Leaf of Chinese character Root of herbaceous plant
1 Pyridine 110-86-1 Pyridine compound — — 0.0649
2 1-Octen-3-ol 3391-86-4 1-octen-3-ol — 0.0394 —
3 (+)-alpha-Longipinene 5989-08-2 Pinene of longleaf 0.9841 1.3309 —
4 delta-Elemene 20307-84-0 Delta-elemene 1.7374 4.837 —
5 beta-Patchoulene 514-51-2 Beta-patchouli alkene 0.6362 0.7467 0.1155
6 (+)-Longicyclene 1137-12-8 (+) -longifolene cycloolefins 0.9665 0.3289 —
7 (-)-beta-Bourbonene 5208-59-3 Beta-bourbonene 0.0718 0.1262 —
8 Linalool 78-70-6 Linalool 0.0925 0.18 0.0253
9 (-)-Aristolene 6831-16-9 Aristolocene 0.3968 0.4728 0.2477
10 (+)-Calarene 17334-55-3 Calamum alkene — — 0.5667
11 beta-Elemene 515-13-9 Beta-elemene 4.1924 8.9869 —
12 beta-Caryophyllene 87-44-5 Trans-caryophyllene 4.8213 8.7899 0.3511
13 Guaia-6,9-diene 36577-33-0 6, 9-guaiadiene — 0.258 —
14 gamma-Elemene 29873-99-2 Gamma-elemene 0.2688 — 0.0757
15 Humulene 6753-98-6 Alpha-humulene 1.0435 2.1611 0.0625
16 gamma-Muurolene 30021-74-0 Gamma-menthalene 0.1281 0.1937 —
17 Borneol 507-70-0 Borneol (borneol) 0.4574 0.5128 0.1253
18 alpha-Selinene 473-13-2 Alpha-sirlinenes — 0.429 —
19 alpha-Muurolene 31983-22-9 Alpha-menthalene — 0.2269 —
20 Bicyclogermacrene 24703-35-3 Bicyclic germacrene — 0.2049 —
21 (+)-delta-Cadinene 483-76-1 (+) -delta-cubebene — 0.5572 —
22 Dihydro-beta-agarofuran 5956-09-2 Dihydro-beta-agarofuran 0.5231 0.6902 —
23 Geraniol 106-24-1 Geraniol — 0.1173 —
24 Caryophyllene oxide 1139-30-6 Dianthus caryophyllus extract 0.4437 0.7705 0.1185
25 Humulene epoxide II 19888-34-7 Epoxidized lupinene II — 0.0956 —
26 Germacrene D-4-ol 198991-79-6 Dextro germacrene-4-ol 0.4812 1.3809 —
27 cis-Eudesm-6-en-11-ol 194607-96-0 Cis-6-eudesmen-11-ol 0.1837 0.1227 0.1483
28 Elemol 639-99-6 Elemenol 4.0112 7.7026 —
29 Guaiol 489-86-1 Guaiol 1.4361 2.6943 —
30 gamma-Eudesmol 1209-71-8 Gamma-eucalyptol 0.797 1.1032 —
31 Methylisoeugenol 93-16-3 Methyl isoeugenol — — 0.5951
32 Hinesol 23811-08-7 Medicinal liquor of Maotai 3.1909 4.2294 —
33 alpha-Eudesmol 473-16-5 Alpha-eucalyptol 0.2395 0.4453 —
34 beta-Eudesmol 473-15-4 Beta-eucalyptol 0.455 0.7904 —
35 Elemicin 487-11-6 Elemene element — — 0.0553
36 alpha-Cadinol 481-34-5 Alpha-cubebinol 0.422 1.2916 0.0827
37 Isospathulenol 88395-46-4 Isobaitol 0.4295 0.8757 —
38 gamma-Asarone 5353-15-1 Gamma-asarone 0.6084 — 1.1339
39 Shyobunol 35727-45-8 Acorus calamus alcohol 1.5507 4.4147 —
40 alpha-Asarone 2883-98-9 Alpha-asarone 29.9203 4.2642 55.8235
41 Isoelemicin 5273-85-8 Isoelemene element 0.1138 — 0.2846
42 beta-Asarone 5273-86-9 Beta-asarone 12.208 2.1328 33.5268
According to GC-MS analysis results, the alpha-asarone (29.9203%) and the beta-asarone (12.208%) are the main components of the whole grass-leaved sweetflag rhizome essential oil; beta-elemene (8.9869%) and trans-caryophyllene (8.7899%) are main components of rhizoma Acori Graminei leaf essential oil; alpha-asarone (55.8235) and beta-asarone (33.5268%) are the main components of the essential oil of Acorus calamus L.
TABLE 3 essential oil of Chimonanthus cheiri
Serial number Name of English CAS Name of Chinese Relative percentage content (%)
1 (1R)-(+)- alpha-Pinene 7785-70-8 Pinene 2.4477
2 (1S)-(1)-beta-Pinene 18172-67-3 L-beta-pinene 1.0644
3 Myrcene 123-35-3 BaylaurelAlkene(s) 1.2875
4 (+)-Dipentene 5989-27-5 (+) -limonene 1.0273
5 1,8-Cineole 470-82-6 Eucalyptol 79.2092
6 Linalool 78-70-6 Linalool 1.3646
7 Terpinyl acetate 80-26-2 Terpinyl acetate 1.1443
8 (-)-alpha-Terpineol 10482-56-1 Alpha-terpineol 4.4237
9 Reynosin 28254-53-7 Chunruokenolide 1.3906
According to the GC-MS analysis result, eucalyptol (79.2092%) is the main component of Chimonanthus cheiri essential oil.
According to the essential oil for relieving rheumatoid arthritis, a TNF-alpha method, a CCK-8 method and ELISA are used for acting on MH7A cells to construct a joint fibroblast synoviocyte inflammation model, the effect of the essential oil on joint synoviocytes is simulated, the effect of the essential oil with different concentrations on human mast cells LAD2 is measured through the CCK-8 method and C48/80, the effect of the essential oil on an immune system is simulated, the essential oil has positive effects on joint synoviocytes inflammation and immune cell functional disorder, the essential oil has practical significance and popularization value, and can be used for relieving the development of products of rheumatoid arthritis.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this application, illustrate embodiments of the invention and, together with the description, serve to explain the invention and not to limit the invention. In the drawings:
FIG. 1 is a graph showing the effect of essential oil components on abnormal proliferation of MH7A cells;
FIG. 2 is a graph of the effect of essential oil composition on MH7A cytokine levels (NO);
FIG. 3 is a graph of the effect of essential oil components on MH7A cytokine levels (IL-1 β);
FIG. 4 is a graph of the effect of essential oil components on MH7A cytokine levels (PEG 2);
FIG. 5 is a graph of the effect of essential oil components on MH7A cell matrix metalloproteinase levels (MMP 3);
FIG. 6 is a graph of the effect of essential oil components on MH7A cell matrix metalloproteinase levels (MMP 1);
FIG. 7 is a graph of the effect of essential oil components on degranulation of LAD2 cells (histamine);
FIG. 8 is a graph of the effect of essential oil content on degranulation of LAD2 cells (tryptase);
FIG. 9 is a graph of the effect of essential oil components on LAD2 cytokine levels (IL-4);
FIG. 10 is a graph of the effect of essential oil components on LAD2 cytokine levels (IL-8);
FIG. 11 is a graph of the effect of essential oil components on LAD2 cytokine levels (TNF-. alpha.);
FIG. 12 is a graph of the effect of essential oil components on LAD2 cytokine levels (VEGF).
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Essential oil for relieving rheumatoid arthritis comprises 1-10g of Chimonanthus nitens essential oil, 1-10g of rhizoma acori graminei essential oil, 1-5g of frankincense essential oil, 1-10g of litsea cubeba essential oil, 1-5g of fir essential oil, 1-10g of hyssop essential oil and 50-100% of black grass oil in the total mass of the rest components.
Example 2
Essential oil for relieving rheumatoid arthritis comprises 1-10g of Chimonanthus cheiri essential oil, 1-10g of rhizoma acori graminei essential oil, 1-5g of frankincense essential oil, 1-10g of litsea cubeba essential oil, 1-5g of fir essential oil, 1-5g of rosemary essential oil and 50-100% of black grass oil in the total mass of the rest components.
With reference to fig. 1, the five plant essential oils all have an inhibiting effect on the abnormal proliferation of the fiber synovial cell MH7A cells under a certain concentration. Wherein 500ug/ml of rhizoma Acori Graminei essential oil has strongest effect, and inhibition rate reaches 41.37%, which is almost equal to positive drug (methotrexate, 41.45%). The three essential oils with inhibition rate of more than 20% are rhizoma Acori Graminei leaf essential oil (100 ug/ml, 200ug/ml, 500 ug/ml), rhizoma Acori Graminei root (200 ug/ml), and Chimonanthus Glabra (500 ug/ml). The inhibition rate of the whole grass-leaved sweetflag rhizome and the Zhejiang wintersweet essential oil with the concentration of 200ug/ml or less is about 10%. The effect of hyssop essential oil on MH7A cell proliferation was weak, with only slight inhibition tendency above 200 ug/ml.
With reference to FIG. 2, the effect of the essential oil components on the level of MH7A cytokine was investigated using three concentrations of 100ug/ml, 200ug/ml and 500ug/ml, which have a better inhibitory effect on MH7A cell proliferation. The five plant essential oils have inhibition effect on NO content of MH7A cells, wherein the inhibition effect of the calamus root and Chimonanthus thunbergii essential oil on NO content is strongest, and is about 24%, and the inhibition effect is more than twice of that of a positive medicine (11.26%). The inhibition rate of the whole grass-leaved sweetflag essential oil is over 20 percent. The inhibition rate of the essential oil of the hyssop and the grass-leaved sweetflag leaf is about 11 percent, and is close to that of a positive medicine.
Referring to FIG. 3, four plant essential oils have inhibitory effect on IL-1. beta. content of MH7A cells. Wherein 200ug/ml of rhizoma Acori Graminei essential oil has strongest effect, and the inhibition rate reaches 23.50% and exceeds that of positive drug (14.98%). In addition, the inhibition rate of hyssop (200 ug/ml) and Zhejiang wintersweet essential oil (100 ug/ml and 200 ug/ml) is more than 15%, and the inhibition rate exceeds that of positive drugs, but the inhibition effect is not achieved at 500 ug/ml. The effect of the grass leaf essential oil is close to that of a positive drug at 500ug/ml, but the effect is not achieved at other concentrations. The whole grass-leaved sweetflag rhizome essential oil has no inhibition effect on the IL-1 beta content.
With the combination of fig. 4, the essential oil component has no inhibition to MH7A cell PEG2, the effect is weak, the inhibition rate of only the grassleaf sweelflag rhizome leaf essential oil is about 10%, and the positive medicine has no inhibition effect to PEG 2.
With reference to fig. 5, four plant essential oils have inhibitory effects on MH7A cell MMP3 content. The inhibition effect of the grass-leaved sweetflag leaves on the MMP3 content is strongest, and is about 15 percent, which exceeds that of positive medicines (9.82 percent). The inhibition rate of the whole essential oil of the hyssop and the grassleaf sweelflag rhizome is more than 10 percent and is also higher than that of the positive medicine. The inhibition effect of the calamus root on the MMP3 content is weak, and is only about 7 percent. The Zhejiang wintersweet essential oil has no inhibition effect on the MMP3 content.
With reference to fig. 6, the three plant essential oils have inhibitory effect on MH7A cell MMP1 content, and all exceed the positive drug. The Zhejiang wintersweet essential oil has the strongest inhibition effect on the MMP1 content, and is about 20%. The inhibition rate of the calamus root on the MMP1 content is about 13%. The whole grass-leaved sweetflag-rhizome essential oil has weak inhibition effect on MMP1 content, and the inhibition effect is about 5%.
With reference to fig. 8, the four plant essential oils have inhibitory effects on tryptase content in human mast cell LAD2 cells. Among them, Chimonanthus thunbergii has the strongest inhibitory action on tryptase content, about 18%, which exceeds that of positive medicine (13.64%). The inhibition rate of the grassleaf sweelflag rhizome leaf essential oil on the tryptase content is more than 10 percent, and the inhibition rate is increased along with the increase of the concentration, and the inhibition rate of 500ug/ml is 16.48 percent. The inhibition effect of the whole grass-leaved sweetflag-rhizome essential oil is weakened along with the increase of the concentration, and the inhibition rate of 0.1ug/ml essential oil is 13.54%. The inhibition effect of the hyssop essential oil on the tryptase content is weak, is only about 7 percent, and is weakened along with the increase of the concentration. The rhizoma Acori Graminei essential oil has no inhibiting effect on tryptase content.
With reference to fig. 9, the grass leaf and the Zhejiang wintersweet essential oil have an inhibitory effect on the IL-4 content of LAD2 cells. The inhibition rate of the Zhejiang wintersweet essential oil is about 18 percent, and exceeds that of a positive medicine (17.16 percent). The inhibition effect of the grassleaf sweelflag rhizome leaf essential oil is enhanced along with the increase of the concentration, the effect is best when the concentration is 500ug/ml, and the inhibition rate is 11.64%.
With reference to fig. 10, the grass-leaved sweetflag leaf and Zhejiang wintersweet essential oil have inhibitory effect on the IL-8 content of LAD2 cells, and the effect is weakened with the increase of the concentration. The inhibition rate of 0.1ug/ml Zhejiang wintersweet essential oil is 22.98%, which exceeds that of positive medicine (18.17%). The inhibition rate of 0.1ug/ml grassleaved sweetflag leaf essential oil is 16.40%, which is close to that of positive medicine.
With reference to fig. 11, the grass-leaved sweetflag leaf, the whole grass-leaved sweetflag and the Chimonanthus chekiangensis essential oil have the effect of inhibiting the TNF-alpha content of the LAD2 cells. The effect of the Zhejiang wintersweet essential oil is best, the effect is enhanced along with the increase of the concentration, the inhibition rate exceeds that of the positive drug when the concentration is more than 100ug/ml, and the inhibition rate of 500ug/ml can reach 27.95%. The inhibition effect of the whole essential oil of the grass-leaved sweetflag leaf and the grass-leaved sweetflag decreases with the increase of the concentration, the best effect is achieved at 0.1ug/ml, and the inhibition rates are respectively 19.40% and 15.09%.
With reference to fig. 12, the grass-leaved sweetflag leaf and Zhejiang wintersweet essential oil have an inhibitory effect on LAD2 cell VEGF content. The 200ug/ml Zhejiang wintersweet essential oil has the best effect, and the inhibition rate is 15.40%. The effect of the grass leaf sweetflag essential oil is enhanced along with the increase of the concentration, and can reach 12.94 percent at 500 ug/ml.
It will be understood by those skilled in the art that the foregoing is merely exemplary of the present invention, and is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

Claims (10)

1. The essential oil for relieving rheumatoid arthritis is characterized in that:
comprises Zhejiang wintersweet essential oil, rhizoma acori graminei essential oil, frankincense essential oil, litsea cubeba essential oil and fir essential oil.
2. The essential oil for relieving rheumatoid arthritis according to claim 1, wherein: 1-10g of Zhejiang wintersweet essential oil, 1-10g of rhizoma acori graminei essential oil, 1-5g of frankincense essential oil, 1-10g of litsea cubeba essential oil and 1-5g of fir essential oil.
3. The essential oil for relieving rheumatoid arthritis according to any one of claims 1-2, wherein: also comprises hyssop essential oil.
4. The essential oil for relieving rheumatoid arthritis according to claim 3, wherein: 1-10g of hyssop essential oil.
5. The essential oil for relieving rheumatoid arthritis according to any one of claims 1-2, wherein: also comprises rosemary essential oil.
6. The essential oil for relieving rheumatoid arthritis according to claim 5, wherein: 1-5g of rosemary essential oil.
7. The essential oil for relieving rheumatoid arthritis according to claim 6, wherein: the rosemary essential oil is verbena ketene type.
8. The essential oil for relieving rheumatoid arthritis according to claim 4 and claim 6, wherein: also includes a diluent.
9. The essential oil for relieving rheumatoid arthritis according to claim 8, wherein: the diluent accounts for 50-100% of the total mass of the rest components.
10. The essential oil for relieving rheumatoid arthritis according to claim 9, wherein: the diluent is black grass oil in specific implementation.
CN202110915803.XA 2021-08-10 2021-08-10 Essential oil for relieving rheumatoid arthritis Pending CN113521171A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110915803.XA CN113521171A (en) 2021-08-10 2021-08-10 Essential oil for relieving rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110915803.XA CN113521171A (en) 2021-08-10 2021-08-10 Essential oil for relieving rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CN113521171A true CN113521171A (en) 2021-10-22

Family

ID=78091456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110915803.XA Pending CN113521171A (en) 2021-08-10 2021-08-10 Essential oil for relieving rheumatoid arthritis

Country Status (1)

Country Link
CN (1) CN113521171A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199833A (en) * 2007-12-21 2008-06-18 北京中科雍和医药技术有限公司 Compound essential oil of releasing arthritis ache
CN106281719A (en) * 2016-10-30 2017-01-04 庞群 The method extracting rosemary ethereal oil from Herba Rosmarini Officinalis grass
CN109846870A (en) * 2019-04-23 2019-06-07 宁夏医科大学 Phenolic acid compound is preparing the purposes in resisting rheumatoid arthritis drug
CN111617199A (en) * 2020-06-30 2020-09-04 王少云 Compound essential oil formula

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199833A (en) * 2007-12-21 2008-06-18 北京中科雍和医药技术有限公司 Compound essential oil of releasing arthritis ache
CN106281719A (en) * 2016-10-30 2017-01-04 庞群 The method extracting rosemary ethereal oil from Herba Rosmarini Officinalis grass
CN109846870A (en) * 2019-04-23 2019-06-07 宁夏医科大学 Phenolic acid compound is preparing the purposes in resisting rheumatoid arthritis drug
CN111617199A (en) * 2020-06-30 2020-09-04 王少云 Compound essential oil formula

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TULIP: "几种对类风湿关节炎有用的精油（之一）_", 《HTTP://WWW.51XINKANG.COM/KNOWLEDGE/2174.HTML》 *
赵萌: "《头部足部穴道按摩方法》", 30 September 2017 *

Similar Documents

Publication Publication Date Title
Asif et al. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties
Fursenco et al. Solidago virgaurea L.: a review of its ethnomedicinal uses, phytochemistry, and pharmacological activities
Yi et al. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice
WO2016103254A1 (en) Use of cannabis to treat psoriasis
Zuo et al. A systematic review of the anti‐inflammatory and immunomodulatory properties of 16 essential oils of herbs
JP2007106774A (en) Chinese herb extract
Zamzami et al. Amelioration of CCl4‐Induced Hepatotoxicity in Rabbits by Lepidium sativum Seeds
Hashmi et al. Nephroprotective effects of Ficus religiosa linn (peepal plant) stem bark against isoniazid and rifampicin induced nephrotoxicity in albino rabbits
Abdel-Azeem et al. Potential renoprotective effects of rosemary and thyme against gentamicin toxicity in rats
Zhang et al. Six herbs essential oils suppressing inflammatory responses via inhibiting COX-2/TNF-α/IL-6/NF-κB activation
Uzor et al. Bioassay guided isolation and evaluation of the antidiabetic principles of Combretum dolichopetalum root
Suroowan et al. Herbal products for common auto-inflammatory disorders-novel approaches
Dey et al. Hepatoprotective Activity of BV‐7310, a Proprietary Herbal Formulation of Phyllanthus niruri, Tephrosia purpurea, Boerhavia diffusa, and Andrographis paniculata, in Alcohol‐Induced HepG2 Cells and Alcohol plus a Haloalkane, CCl4, Induced Liver Damage in Rats
Kaur et al. Pharmacodynamic interaction of cumin seeds (Cuminum cyminum L.) with glyburide in diabetes
CN113521171A (en) Essential oil for relieving rheumatoid arthritis
Ghorani et al. The effect of Zataria multiflora on respiratory allergic and immunologic disorders, experimental and clinical evidence: A comprehensive review
Gnananath et al. Evaluation of antidiabetic activity in Corallocarpus epigaeus rhizomes
Sani et al. Suppressive effects of medicinal plants and their derivatives on inflammasome complex: A systematic review
Yang et al. The combination of two natural medicines, chuanxiong and asarum: A review of the chemical constituents and pharmacological activities
Burlou-Nagy et al. Echinacea purpurea (L.) Moench: biological and pharmacological properties. A review. Plants. 2022. 11: 1244
Okhale et al. Aristolochic acids in herbal medicine: Public health concerns for consumption and poor regulation of botanical products in Nigeria and West Africa
Fu et al. Protective effects and possible mechanisms of catalpol against diabetic nephropathy in animal models: a systematic review and meta-analysis
Maseehullah et al. Ethno-pharmacology of Asaroon (Asarum europaeum L.) with special reference to Unani System of Medicine
Tisserand et al. Debunking functional group theory: Not supported by current evidence and not a useful educational tool
Kavitha et al. In vitro study on Antiinflammatory activity of aqueous extract of Vateria indica resin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211022